| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4dc42489d4d5995ea72c0615204738c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2021-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5155ec829726d258887a8be444c7f009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_729d0f386a8b95d41c702432c0f25a1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_433f127af19f876aa9d3a016237ce11f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10024e21080ff0ce682579934f0b936c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_085afb1cd6dd89487a2c610647936dba |
| publicationDate |
2022-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202227077-A |
| titleOfInvention |
Use of an erk inhibitor for the treatment of myelofibrosis |
| abstract |
The invention relates to the use of an ERK inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an ERK inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |